XTX Topco Ltd Raises Stock Holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

Key Points

• XTX Topco Ltd significantly increased its holdings in IDEAYA Biosciences by 138.3% during the first quarter, bringing its total position to 30,215 shares worth $495,000.
• IDEAYA Biosciences' stock experienced a 3.1% increase in trading, now priced at $23.10, with a market cap of $2.02 billion and a current P/E ratio of -6.09.
• Multiple research firms have recently provided positive outlooks on IDEAYA, with target prices ranging significantly, including an upgrade by JPMorgan Chase & Co. to $72.00, indicating strong confidence in the company's future performance.

XTX Topco Ltd grew its holdings in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 138.3% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 30,215 shares of the company's stock after acquiring an additional 17,536 shares during the quarter. XTX Topco Ltd's holdings in IDEAYA Biosciences were worth $495,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of IDYA. JPMorgan Chase & Co. boosted its position in shares of IDEAYA Biosciences by 244.3% during the 4th quarter. JPMorgan Chase & Co. now owns 274,693 shares of the company's stock valued at $7,060,000 after acquiring an additional 194,913 shares during the last quarter. Geode Capital Management LLC lifted its position in IDEAYA Biosciences by 2.2% in the 4th quarter. Geode Capital Management LLC now owns 1,988,681 shares of the company's stock worth $51,121,000 after buying an additional 43,226 shares during the last quarter. FMR LLC lifted its position in IDEAYA Biosciences by 2.6% in the 4th quarter. FMR LLC now owns 12,963,151 shares of the company's stock worth $333,153,000 after buying an additional 327,498 shares during the last quarter. Legal & General Group Plc lifted its position in IDEAYA Biosciences by 7.9% in the 4th quarter. Legal & General Group Plc now owns 82,442 shares of the company's stock worth $2,119,000 after buying an additional 6,064 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its position in IDEAYA Biosciences by 66.9% in the 4th quarter. Renaissance Technologies LLC now owns 284,267 shares of the company's stock worth $7,306,000 after buying an additional 113,902 shares during the last quarter. Institutional investors own 98.29% of the company's stock.

IDEAYA Biosciences Stock Up 2.6%

Shares of IDYA traded up $0.59 during mid-day trading on Tuesday, hitting $23.43. 89,670 shares of the company's stock traded hands, compared to its average volume of 1,148,786. IDEAYA Biosciences, Inc. has a 1 year low of $13.45 and a 1 year high of $40.74. The firm has a market capitalization of $2.05 billion, a P/E ratio of -6.17 and a beta of 0.09. The business's 50-day moving average price is $22.51 and its 200-day moving average price is $20.34.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last posted its earnings results on Tuesday, August 5th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.85) by ($0.03). The firm had revenue of $6.00 million during the quarter, compared to analysts' expectations of $3.48 million. During the same quarter in the previous year, the business earned ($0.68) earnings per share. The business's revenue for the quarter was up NaN% on a year-over-year basis. Sell-side analysts anticipate that IDEAYA Biosciences, Inc. will post -3.07 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the company. TD Cowen assumed coverage on IDEAYA Biosciences in a research report on Tuesday, July 22nd. They issued a "buy" rating for the company. JPMorgan Chase & Co. boosted their target price on IDEAYA Biosciences from $66.00 to $72.00 and gave the stock an "overweight" rating in a research report on Monday, July 28th. Wells Fargo & Company started coverage on IDEAYA Biosciences in a research report on Thursday, June 26th. They issued an "overweight" rating and a $44.00 target price for the company. Royal Bank Of Canada raised IDEAYA Biosciences from an "outperform" rating to a "moderate buy" rating and decreased their price target for the stock from $57.00 to $30.00 in a research note on Wednesday, July 9th. Finally, The Goldman Sachs Group upgraded IDEAYA Biosciences to a "hold" rating and set a $25.00 price objective for the company in a research report on Thursday, July 10th. Three analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $48.09.

IDEAYA Biosciences Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.